Recall archive / FDA drug enforcement
ceFAZolin sodium in Sterile Water for injection, Injectable Solution, 1g/10mL (0.1 g per mL), Syringe, Rx only, Wells... — FDA record D-0141-2024
Reported completed
Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.
Source date Nov 22, 2023. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
What the record says
- Product
- ceFAZolin sodium in Sterile Water for injection, Injectable Solution, 1g/10mL (0.1 g per mL), Syringe, Rx only, Wells Pharma, NDC 73702-131-10
- Reason
- Lack of assurance of sterility.
- Classification
- Class II
- Recalling firm
- Wells Pharma of Houston LLC
- Quantity
- 825 syringes
- Agency-reported status
- Completed
- Source record identifier
- D-0141-2024
What the recall classes mean. Classification is an agency assessment, not individual medical advice.
Lot and product identifiers
| Label field | Details supplied by the agency |
|---|---|
| Lot, code or applicability | Lot # 11092313110#01, Exp 01/12/24 |
Match all identifying details in the current notice. A brand name alone is not enough.
Distribution
Philadelphia, Pennsylvania.
States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.
Dates in the source
- Report date
- Dec 13, 2023
- Recall initiation date
- Nov 22, 2023
- Center classification date
- Dec 6, 2023
FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.